Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
ESMO 2017: Prostate cancer highlights

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 2941

Prof Karim Fizazi, Prof Stephane Oudard, Dr Bertrand Tombal & Prof Maria De Santis

Our panel of experts share their ESMO 2017 highlights and offer their opinion on current, and future standard-of-care within prostate cancer treatment. Some of the panels key highlights include additional STAMPEDE data which share further efficacy results; this time assessing the addition of abiraterone acetate plus prednisolone vs. docetaxel for patients with high risk prostate cancer starting long-term androgen deprivation therapy; and additional data from STAMPEDE looking at the outcomes in non-metastatic (M0) patients.

Further data from LATITUDE, looked at patient reported outcomes (PRO) and the interpretation of the data from FACT-P and EQ-5D-5L questionnaires, with some key significant parameters being delayed time to pain and fatigue intensity and interference progression shown in the ADT AA P arm.

Phase 3 results were discussed, assessing whether docextaxel with androgen suppression for high-risk localised prostate cancer for patients with relapsing PSA after radical prostatectomy and/or radiotherapy - the trial was designed to compare AS (triptorelin, every 3 months for 1 year) versus AS D in patients with ≥ 3 rising PSA values.

Our panel also discussed the ARASENS trial, which is evaluating darolutamide plus standard ADT þ docetaxel in men with mHSPC, and the TRITON clinical trial programme, evaluating the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). This trial raised further discussion on the need for guidelines to signpost what patients will require BRCA germline and somatic testing in the future.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence